Proteins.1 Reinvents Diagnostics: Unlocks 1,000x Sensitivity for Early Disease Detection
April 27, 2026, 3:37 am
Proteins.1 secured €4.7M in pre-seed funding. This Finnish deep-tech firm revolutionizes diagnostics. Their patented platform amplifies single protein molecules. It offers PCR-like sensitivity for proteins. No prior equivalent existed for detecting early disease markers. Diseases like cancer, neurodegeneration, and inflammatory conditions will see earlier, more precise detection. The technology is 1,000 times more sensitive. It analyzes hundreds of biomarkers from tiny blood samples. This solid-state, enzyme-free approach targets research and clinical markets. It heralds a new era in medical diagnostics, aiming to become a European tech hub.
Proteins.1 has launched. It secured €4.7 million in pre-seed funding. This Finnish deep-tech startup aims to transform medical diagnostics. Their breakthrough technology offers unprecedented sensitivity. It targets a long-standing gap in disease detection.
The funding round was substantial. Lifeline Ventures and Cloudberry Ventures led the investment. VTT, Finland’s national research organization, provided in-kind support. Business Finland also contributed. This capital fuels the company's ambitious plans.
Proteins are crucial. They are the earliest indicators of many diseases. Cancer, neurodegeneration, cardiovascular disease, and inflammatory conditions often manifest first through protein changes. Current diagnostic methods struggle to detect these early signals. A lack of protein amplification limits progress.
Proteins.1 solves this. Their patented platform brings PCR-like amplification to proteins. PCR revolutionized DNA detection. Proteins.1 now offers an equivalent for proteins. This innovation changes the game.
The technology is physics-based. It employs a magnetic cycling mechanism. This mechanism repeatedly reads a single captured protein molecule. Signal clarity accumulates. Background noise does not increase. This method is highly precise.
Existing immunoassays are different. They rely on enzymatic reactions. These reactions introduce variability. They often create background noise. Proteins.1 avoids these issues. Its approach is solid-state. It is enzyme-free. It seamlessly integrates with semiconductor-based photonic detection. This design ensures robustness and reliability.
The impact is profound. Detection sensitivity increases by up to 1,000 times. This allows for earlier diagnosis. It enables more accurate disease monitoring. Small changes become visible. Previously undetectable signals now appear. This is a leap forward for protein diagnostics.
High multiplexing is another key feature. The platform can measure hundreds of biomarkers simultaneously. It needs only a few drops of blood. This comprehensive analysis is crucial for complex diseases. It provides a holistic view of patient health. Capital costs remain lower than incumbent systems. This makes advanced diagnostics more accessible.
Proteins.1 will first target research-use-only applications. Oncology, neurology, and immunology are initial focus areas. Researchers will gain powerful new tools. They can accelerate discovery. They can develop new therapies faster. This lays the groundwork for clinical use.
The global diagnostics market is vast. It exceeds €100 billion annually. Demand for early detection continues to grow. Multi-omic analysis is becoming essential. Proteins.1 is perfectly positioned to capitalize on these trends. Its technology aligns with future diagnostic needs.
The founding team is strong. CEO and co-founder Prateek Singh invented the core technology. He has a history of successful microfluidics ventures. He holds multiple patent families. COO and co-founder Harri Hallila brings extensive experience. He built and exited a regulated medical device company. Their combined expertise drives Proteins.1.
The company plans significant expansion. Engineering and product development teams will grow in Finland. This growth is scheduled for 2026 and 2027. Proteins.1 aims to become a European hub. It seeks to lead next-generation diagnostic technology. This strengthens Europe's deep-tech ecosystem.
This technology promises to transform medicine. It offers the potential for earlier interventions. Patients can receive treatment sooner. Outcomes can improve dramatically. The diagnostic landscape will evolve. Precision medicine relies on such advancements.
Proteins.1 closes a critical gap in medical science. It provides the long-awaited equivalent to PCR for proteins. This breakthrough represents a new era in molecular diagnostics. It is a powerful tool for fighting disease. The future of sensitive, early disease detection is here.
Proteins.1 has launched. It secured €4.7 million in pre-seed funding. This Finnish deep-tech startup aims to transform medical diagnostics. Their breakthrough technology offers unprecedented sensitivity. It targets a long-standing gap in disease detection.
The funding round was substantial. Lifeline Ventures and Cloudberry Ventures led the investment. VTT, Finland’s national research organization, provided in-kind support. Business Finland also contributed. This capital fuels the company's ambitious plans.
Proteins are crucial. They are the earliest indicators of many diseases. Cancer, neurodegeneration, cardiovascular disease, and inflammatory conditions often manifest first through protein changes. Current diagnostic methods struggle to detect these early signals. A lack of protein amplification limits progress.
Proteins.1 solves this. Their patented platform brings PCR-like amplification to proteins. PCR revolutionized DNA detection. Proteins.1 now offers an equivalent for proteins. This innovation changes the game.
The technology is physics-based. It employs a magnetic cycling mechanism. This mechanism repeatedly reads a single captured protein molecule. Signal clarity accumulates. Background noise does not increase. This method is highly precise.
Existing immunoassays are different. They rely on enzymatic reactions. These reactions introduce variability. They often create background noise. Proteins.1 avoids these issues. Its approach is solid-state. It is enzyme-free. It seamlessly integrates with semiconductor-based photonic detection. This design ensures robustness and reliability.
The impact is profound. Detection sensitivity increases by up to 1,000 times. This allows for earlier diagnosis. It enables more accurate disease monitoring. Small changes become visible. Previously undetectable signals now appear. This is a leap forward for protein diagnostics.
High multiplexing is another key feature. The platform can measure hundreds of biomarkers simultaneously. It needs only a few drops of blood. This comprehensive analysis is crucial for complex diseases. It provides a holistic view of patient health. Capital costs remain lower than incumbent systems. This makes advanced diagnostics more accessible.
Proteins.1 will first target research-use-only applications. Oncology, neurology, and immunology are initial focus areas. Researchers will gain powerful new tools. They can accelerate discovery. They can develop new therapies faster. This lays the groundwork for clinical use.
The global diagnostics market is vast. It exceeds €100 billion annually. Demand for early detection continues to grow. Multi-omic analysis is becoming essential. Proteins.1 is perfectly positioned to capitalize on these trends. Its technology aligns with future diagnostic needs.
The founding team is strong. CEO and co-founder Prateek Singh invented the core technology. He has a history of successful microfluidics ventures. He holds multiple patent families. COO and co-founder Harri Hallila brings extensive experience. He built and exited a regulated medical device company. Their combined expertise drives Proteins.1.
The company plans significant expansion. Engineering and product development teams will grow in Finland. This growth is scheduled for 2026 and 2027. Proteins.1 aims to become a European hub. It seeks to lead next-generation diagnostic technology. This strengthens Europe's deep-tech ecosystem.
This technology promises to transform medicine. It offers the potential for earlier interventions. Patients can receive treatment sooner. Outcomes can improve dramatically. The diagnostic landscape will evolve. Precision medicine relies on such advancements.
Proteins.1 closes a critical gap in medical science. It provides the long-awaited equivalent to PCR for proteins. This breakthrough represents a new era in molecular diagnostics. It is a powerful tool for fighting disease. The future of sensitive, early disease detection is here.